Immune checkpoint inhibitors inhibit the inhibitory mechanism on the immune system, their side effects may be autoimmune diseases that occur due to excessive immune response. Pembrolizumab is an immune checkpoint inhibitor targeting PD-1. The most common clinical presentations of thyroid injury induced by pembrolizumab are destructive thyroiditis and overt hypothyroidism. Herein, we presented a case of pembrolizumab induced hypothyroidism.
Pembrolizumab immune checkpoint inhibitors lung cancer hypothyroidism PD-1 non-small cell lung
Primary Language | English |
---|---|
Subjects | Internal Diseases |
Journal Section | Case Reports |
Authors | |
Publication Date | April 1, 2022 |
Submission Date | February 24, 2022 |
Acceptance Date | March 9, 2022 |
Published in Issue | Year 2022 Volume: 4 - Supplement 1 |